Translation of innovative designs into phase I trials

Journal of Clinical Oncology

Volumn 25, Issue 31, 2007, Pages 4982-4986

  Rogatko, André ^a   Schoeneck, David ^a   Jonas, William ^a   Tighiouart, Mourad ^a   Khuri, Fadlo R ^a   Porter, Alan ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; CLINICAL PRACTICE; HUMAN; MEDICAL RECORD; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PUBLICATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DIFFUSION OF INNOVATION; HUMANS; NEOPLASMS; RESEARCH DESIGN; THERAPIES, INVESTIGATIONAL;

EID: 36849035490     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.1012     Document Type: Article

References (31)

1. American Cancer Society: Cancer Facts and Figures 2007. http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp
2. Pharmaceutical Research and Manufacturers of America: Medicines in development. http://www.phrma.org/newmedicines/resources
3. Roberts TG Jr, Goulart BH, Squitieri L, et al: Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130-2140, 2004
4. National Institutes of Health: ClinicalTrials .gov.http://www. clinicaltrials.gov
5. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 46:33-48, 1990
6. National Center for Biotechnology Information: PubMed. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
7. Thomson Scientific: Science Citation Index Expanded. http://scientific. thomson.com/products/scie/
8. Search Technology Inc: VantagePoint. http://www.thevantagepoint.com/
9. Dixon WJ, Mood AM: A method for obtaining and analyzing sensitivity data. J Am Stat Assoc 43:109-126, 1948
10. Rosenberger WF, Haines LM: Competing designs for phase I clinical trials: A review. Stat Med 21:2757-2770, 2002
11. Potter DM: Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer. Stat Med 21:1805-1823, 2002
12. Goodman SN, Zahurak ML, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149-1161, 1995
13. O'Quigley J, Shen LZ: Continual reassessment method: A likelihood approach. Biometrics 52:673-684, 1996
14. Babb JS, Rogatko A: Patient specific dosing in a cancer phase I clinical trial. Stat Med 20:2079-2090, 2001
15. Zacks S, Rogatko A, Babb J: Optimal Bayesianfeasible dose escalation for cancer phase I trials. Stat Prob Lett 38:215-220, 1998
16. Tighiouart M, Rogatko A, Babb JS: Flexible Bayesian methods for cancer phase I clinical trials: Dose escalation with overdose control. Stat Med 24:2183-2196, 2005
17. Chandra P, Weisstein EW: Fibonacci number. http://mathworld.wolfram.com/ FibonacciNumber.html
18. Omura GA: Modified Fibonacci search. J Clin Oncol 21:3177, 2003
19. Black PE: Dictionary of Algorithms and Data Structures. http://www.nist.gov/dads/HTML/fibonaccianSearch.html
20. Brownlee KA, Hodges JL, Rosenblatt M: The up-and-down method with small samples. Am Stat Assoc J 48:262-277, 1953
21. Ivanova A, Flournoy N: Group up-and-down designs in toxicity studies, in Chevret S (ed): Statistical Methods for Dose-Finding Experiments (ed 1). West Sussex, United Kingdom, John Wiley and Sons, Ltd, 2006, pp 115-128
22. Edler L: Statistical requirements of phase I studies. Onkologie 13:90-95, 1990
23. Storer BE: Design and analysis of phase I clinical trials. Biometrics 45:925-937, 1989
24. O'Quigley J: Theoretical study of the continual reassessment method. J Stat Planning Inference 136:1765-1780, 2006
25. O'Quigley J, Chevret S: Methods for dose finding studies in cancer clinical trials: A review and results of a Monte Carlo study. Stat Med 10:1647-1664, 1991
26. Babb J, Rogatko A, Zacks S: Cancer phase I clinical trials: Efficient dose escalation with overdose control. Stat Med 17:1103-1120, 1998
27. Rogatko A, Babb JS, Tighiouart M, et al: New paradigm in dose-finding trials: Patient-specific dosing and beyond phase I. Clin Cancer Res 11:5342-5346, 2005
28. Dent SF, Eisenhauer EA: Phase I trial design: Are new methodologies being put into practice? Ann Oncol 7:561-566, 1996
29. Roessner D, Bozeman B, Feller I, et al: The role of NSF's Support of Engineering in Enabling Technological Innovation, First Year Final Report, Washington, DC, SRI International, The Science and Technology Policy Program, 1997
30. Illinois Institute of Technology Research: Technology in Retrospect and Critical Events in Science. Washington, DC, National Science Foundation, Illinois Institute of Technology Research, 1968
31. Tornatzky L, Fleischer M: The Process of Technological Innovation. Lexington, MA, Lexington Books, 1990